HOME >> BIOLOGY >> NEWS
Life expectancy following diagnosis of Alzheimers disease depends on age at diagnosis

The life span of people with Alzheimer's disease depends greatly on the age of the person when Alzheimer's disease is diagnosed, according to a study by researchers at the Johns Hopkins Bloomberg School of Public Health. Determining the survival following a diagnosis of Alzheimer's disease is important information for helping patients, families, and their caregivers, deal with the illness. The findings are published in the November 18, 2002, edition of Archives of Neurology.

"The duration of survival following a diagnosis of Alzheimer's disease depends critically on the subject's age at diagnosis. The results of this study indicate that the median survival of patients with Alzheimer's disease could range from nearly 9 years for persons diagnosed at age 65 to approximately 3 years for persons diagnosed at age 90 years," said Ronald Brookmeyer, PhD, professor of biostatistics at the Johns Hopkins Bloomberg School of Public Health.

Data for the study was collected from the Baltimore Longitudinal Study of Aging, which began in 1958 to monitor the effects of aging. The participants were asked to return for follow-up visits every two years to be examined and to answer questionnaires. From this study, Dr. Brookmeyer and his colleagues selected 921 participants who were age 55 or older in 1985 and had received some follow-up visits. Alzheimer's disease was diagnosed using several neuropsychological tests and deaths were recorded through September 1999.

The statistical analysis found that the median survival times ranged from 8.3 years for people diagnosed at age 65 to 3.4 years for people diagnosed at age 90. Persons diagnosed with Alzheimer's disease at age 65 could anticipate a 67 percent reduction in life span compared to those without Alzheimer's disease, while persons diagnosed at age 90 could anticipate a 39 percent reduction in life span. The researchers say Alzheimer's disease is associated with a greater proportionate reduction of life span
'"/>

Contact: Tim Parsons
paffairs@jhsph.edu
410-955-6878
Johns Hopkins University Bloomberg School of Public Health
18-Nov-2002


Page: 1 2

Related biology news :

1. Common variation of klotho gene associated with human life expectancy
2. Phase II trials of second-generation antisense cancer drug planned following successful early study
3. Putting GPS to work, researchers shed light on road-following by pigeons
4. Tamoxifen stimulates breast cancer growth following alteration of estrogen receptor
5. Leave land alone following natural disasters, say researchers
6. Complement inhibitor decreases heart attacks and death in men following cardiac surgery
7. Researchers learn certain enzyme inhibitors may help in cancer therapy following initial procedures
8. Gene more than doubles risk of depression following life stresses
9. Dyslexic children`s brains operate more like those of normal readers following training
10. A new study sheds light on how the tongue restores its ability to taste following surgery
11. Hopkins researchers find postoperative fevers common following hemispherectomy

Post Your Comments:
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... CT ., Aug. 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces it has joined The Smart Card Alliance and ... Smart Card Alliance and the Smart Card Alliance Latin ... visibility to industry peers and thought leaders promoting adoption ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:8/28/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: ... the development of autologous cell therapies, today reported ... 2015, corporate highlights, and near-term milestones.  The company,s ... www.sedar.com ,  www.edgar.com and at ... to launch its RCS-01 treatment for aging and ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas ... investment firms and animal health companies to hear from animal health companies with ... have also received licensing agreements or distribution contracts. This meeting is one ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
Cached News: